NTRA News and Press, Natera Inc. From 10/26/22

Summary The FDA is preparing to extend its regulatory arm over LDTs. The potential for negative regulatory intervention puts OCX's strategy into serious question. OCX must navigate the new regulations and the limited resources that come with being a small-cap company while try...

Summary The introduction of new products and the further extension of reimbursement routes are projected to fuel CDNA growth. CDNA is renewing its emphasis on profitability after a widening loss caused a 14% share decline in August after the Q2 earnings release. CDNA is in a b...

Summary Guardant Health derives most of its revenue from FDA-approved liquid-biopsy services as opposed to CLIA-waived laboratory-developed tests "LDT". As the FDA prepares to extend its regulatory arm over LDT, it might be a good idea to shift your investment exposure to companie...

Summary Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages. Other healthcare industries don’t look attractive. Focus on a biotech ETF: GNOM (and why I don’t like it). ...

Summary Media reports of dramatic consequences of incorrect gene test interpretation and use combined with allegations of aggressive billing tactics drove the NTRA shares reeling. This negative publicity alienated investors who seem to miscalculate its impact on NTRA's revenu...

New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer PR Newswire Multi-site study shows personalized ctDNA analysis is highly prognostic of recurrence-free survival and outperforms CA-125 in identifying patients at high risk of...

Natera, Inc. ( NASDAQ: NTRA ), a company focused on molecular testing, added ~7% intraday Tuesday on the announcement of peer-reviewed data highlighting the potential of its Prospera Kidney test in monitoring potential transplant rejection. The Trifecta study was desig...

Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection PR Newswire AUSTIN, Texas , Oct. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) ...

Summary There is a high chance that the Illumina, Inc.-Grail deal would collapse after European regulators decide to block the acquisition. Without Grail, I believe Illumina will find it hard to maintain growth in light of disruptions in its end markets, namely the clinical gene t...

Natera Announces 2025 ESG Goals with Publication of 2021 Report PR Newswire AUSTIN, Texas , Sept. 29, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of ...